JP2019526606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526606A5 JP2019526606A5 JP2019513756A JP2019513756A JP2019526606A5 JP 2019526606 A5 JP2019526606 A5 JP 2019526606A5 JP 2019513756 A JP2019513756 A JP 2019513756A JP 2019513756 A JP2019513756 A JP 2019513756A JP 2019526606 A5 JP2019526606 A5 JP 2019526606A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- compound according
- pneumonitis
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 206010035664 Pneumonia Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 206010035742 Pneumonitis Diseases 0.000 claims 8
- 208000011580 syndromic disease Diseases 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 6
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Chemical group 0.000 claims 4
- 229910052717 sulfur Chemical group 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 150000003852 triazoles Chemical group 0.000 claims 4
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 101150094373 Padi4 gene Proteins 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000027932 Collagen disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 2
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000002956 necrotizing effect Effects 0.000 claims 2
- 230000036281 parasite infection Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003402 Arthropod sting Diseases 0.000 claims 1
- 206010003504 Aspiration Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 206010004485 Berylliosis Diseases 0.000 claims 1
- 208000009766 Blau syndrome Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000023355 Chronic beryllium disease Diseases 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 201000011275 Epicondylitis Diseases 0.000 claims 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000035690 Familial cold urticaria Diseases 0.000 claims 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims 1
- 206010070531 Foetal growth restriction Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020575 Hyperammonaemia Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010024238 Leptospirosis Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010065838 Middle ear inflammation Diseases 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010070594 PFAPA syndrome Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241001442654 Percnon planissimum Species 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 208000012641 Pigmentation disease Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039792 Seborrhoea Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000004760 Tenosynovitis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000002561 chemical irritant Substances 0.000 claims 1
- 201000004018 childhood brain stem glioma Diseases 0.000 claims 1
- 201000004709 chorioretinitis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002169 ectodermal dysplasia Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010015907 eye allergy Diseases 0.000 claims 1
- 208000030941 fetal growth restriction Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 201000003535 hypohidrotic ectodermal dysplasia Diseases 0.000 claims 1
- 208000035128 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 10B Diseases 0.000 claims 1
- 208000032771 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 11B Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 201000003265 lymphadenitis Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000010346 psychosocial stress Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393209P | 2016-09-12 | 2016-09-12 | |
| US62/393,209 | 2016-09-12 | ||
| PCT/US2017/050886 WO2018049296A1 (en) | 2016-09-12 | 2017-09-11 | Heteroaryl inhibitors of pad4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526606A JP2019526606A (ja) | 2019-09-19 |
| JP2019526606A5 true JP2019526606A5 (enExample) | 2020-10-22 |
| JP7118951B2 JP7118951B2 (ja) | 2022-08-16 |
Family
ID=59955657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513756A Active JP7118951B2 (ja) | 2016-09-12 | 2017-09-11 | Ｐａｄ４のヘテロアリール阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11026937B2 (enExample) |
| EP (1) | EP3510025B1 (enExample) |
| JP (1) | JP7118951B2 (enExample) |
| KR (1) | KR102502992B1 (enExample) |
| CN (1) | CN110248934B (enExample) |
| ES (1) | ES2924522T3 (enExample) |
| MA (1) | MA46193A (enExample) |
| WO (1) | WO2018049296A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201807021UA (en) | 2016-02-23 | 2018-09-27 | Padlock Therapeutics Inc | Heteroaryl inhibitors of pad4 |
| US10703741B2 (en) | 2016-07-27 | 2020-07-07 | Padlock Therapeutics, Inc. | Covalent inhibitors of PAD4 |
| WO2019222093A1 (en) * | 2018-05-14 | 2019-11-21 | Ariad Pharmaceuticals, Inc. | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders |
| KR102089476B1 (ko) * | 2018-07-11 | 2020-03-16 | 이화여자대학교 산학협력단 | 피부 염증 질환 예방 또는 치료용 조성물 |
| ES2929200T3 (es) | 2018-08-08 | 2022-11-25 | Bristol Myers Squibb Co | Tienopirroles sustituidos como inhibidores de PAD4 |
| ES2956090T3 (es) | 2018-08-08 | 2023-12-13 | Bristol Myers Squibb Co | Inhibidores de bencimidazol de enzimas PAD |
| EP3833440A1 (en) | 2018-08-08 | 2021-06-16 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of pad enzymes |
| CN109467549B (zh) * | 2018-12-07 | 2021-02-09 | 中国药科大学 | 喹啉取代查尔酮类化合物、其制备方法及用途 |
| KR102173983B1 (ko) | 2019-04-18 | 2020-11-04 | 현대모비스 주식회사 | 전자식 유압 브레이크 장치 |
| CN115298175B (zh) | 2020-02-06 | 2024-05-07 | 百时美施贵宝公司 | 可用作免疫抑制剂的大环pad4抑制剂 |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| MX2022013615A (es) | 2020-04-30 | 2022-11-16 | Gilead Sciences Inc | Inhibidores de macrociclo de peptidilarginina deiminasas. |
| EP4267562A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| WO2024112749A1 (en) * | 2022-11-23 | 2024-05-30 | The Children's Medical Center Corporation | Methods of treating heart failure |
| CN115778930B (zh) * | 2022-12-08 | 2024-02-27 | 陕西中医药大学 | 一种具有血管舒张活性的二硫缩醛类化合物在制备具有血管舒张活性药物方面的应用 |
| US11731942B1 (en) | 2023-01-12 | 2023-08-22 | King Faisal University | 3-substituted quinolin-2-one compounds as antibacterial agents |
| JP7742517B2 (ja) * | 2023-02-28 | 2025-09-19 | 中外製薬株式会社 | Ｍｙｔ１阻害活性を有する含窒素複素環化合物 |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000047205A1 (en) | 1999-02-10 | 2000-08-17 | The Trustees Of The University Of Pennsylvania | Tyrosine kinase inhibitors and methods of using the same |
| EP1404329A4 (en) | 2001-06-04 | 2006-11-02 | Cytovia Inc | QUINOLINONES 4-ARYL-3- (3-ARYL-1-OXO-2-PROPENYL) -2 (1H) -US SUBSTITUTED, AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS, AND RELATIVE USE |
| JP2002371078A (ja) | 2001-06-12 | 2002-12-26 | Sankyo Co Ltd | キノリン誘導体及びキノロン誘導体 |
| CA2538960C (en) * | 2003-09-17 | 2013-03-19 | Sumitomo Chemical Company, Limited | Cinnamoyl compound and use of the same |
| JP4815773B2 (ja) | 2003-09-17 | 2011-11-16 | 住友化学株式会社 | シンナモイル化合物及びその用途 |
| AU2005253966B2 (en) | 2004-06-08 | 2012-01-19 | Temple University Of The Commonwealth System Of Higher Education | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof |
| CA2600287A1 (en) | 2005-03-02 | 2006-09-08 | Sumitomo Chemical Company, Limited | Use of cinnamoyl compound |
| JP2006273848A (ja) | 2005-03-02 | 2006-10-12 | Sumitomo Chemical Co Ltd | シンナモイル化合物の用途 |
| CA2611608A1 (en) | 2005-06-08 | 2006-12-14 | Temple University - Of The Commonwealth System Of Higher Education | 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof |
| ES2431466T3 (es) | 2006-06-30 | 2013-11-26 | Sunesis Pharmaceuticals, Inc. | Inhibidores de piridinonil pdk1 |
| EP1987717A1 (de) * | 2007-04-30 | 2008-11-05 | Bayer CropScience AG | Pyridoncarboxamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| US20120190707A1 (en) | 2008-04-25 | 2012-07-26 | Ronai Ze Ev | Selective inhibitors of akt and methods of using same |
| RU2611010C2 (ru) * | 2012-07-26 | 2017-02-17 | Глаксо Груп Лимитед | 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4 |
| CN105315333A (zh) | 2014-06-10 | 2016-02-10 | 首都医科大学 | 异喹啉-3-甲酰-RV-OBzl,其制备,纳米结构,活性和应用 |
| US10577349B2 (en) | 2015-03-02 | 2020-03-03 | Sanford Burnham Prebys Medical Discovery Institute | Quinolinones as inhibitors of translation initiation complex |
| WO2016185279A1 (en) | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| AR107030A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| SG11201807021UA (en) | 2016-02-23 | 2018-09-27 | Padlock Therapeutics Inc | Heteroaryl inhibitors of pad4 |
| CN105820058A (zh) | 2016-03-01 | 2016-08-03 | 南开大学 | 精氨酸脱亚氨酶4的新型抑制剂 |
| US10703741B2 (en) | 2016-07-27 | 2020-07-07 | Padlock Therapeutics, Inc. | Covalent inhibitors of PAD4 |
-
2017
- 2017-09-11 KR KR1020197010110A patent/KR102502992B1/ko active Active
- 2017-09-11 MA MA046193A patent/MA46193A/fr unknown
- 2017-09-11 EP EP17772181.8A patent/EP3510025B1/en active Active
- 2017-09-11 WO PCT/US2017/050886 patent/WO2018049296A1/en not_active Ceased
- 2017-09-11 ES ES17772181T patent/ES2924522T3/es active Active
- 2017-09-11 US US16/331,622 patent/US11026937B2/en active Active
- 2017-09-11 JP JP2019513756A patent/JP7118951B2/ja active Active
- 2017-09-11 CN CN201780070039.2A patent/CN110248934B/zh active Active
-
2021
- 2021-05-12 US US17/318,078 patent/US20210299115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019525936A5 (enExample) | ||
| JP2019505568A5 (enExample) | ||
| JP2019505597A5 (enExample) | ||
| ES2295682T3 (es) | Derivados de pirimidina y su uso como modulares de cb2. | |
| JP6181060B2 (ja) | Ｎ−ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのアリール尿素誘導体 | |
| EP0815861B1 (de) | Sulfonamide und ihre Verwendung | |
| RU2167874C2 (ru) | Производные хинолин-2(1н)-она, способы их получения, лекарственное средство и фармацевтическая композиция на их основе | |
| JP5982001B2 (ja) | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 | |
| RU2010116182A (ru) | Октагидропенталеновые соединения в качестве антагонистов хемокиновых рецепторов | |
| DE69619381T2 (de) | 1h-4(5)substituierte imidazolderivate | |
| DE69923300T2 (de) | Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
| JP2021105002A5 (enExample) | ||
| JP2021535174A5 (enExample) | ||
| JPH10502640A (ja) | 異項環タキキニン受容体拮抗物質 | |
| US20120225937A1 (en) | Crystalline forms and processes for the preparation of pg12 receptor agonists | |
| JP2005505618A5 (enExample) | ||
| DE69634416T2 (de) | Chinolin-derivate | |
| PT88662B (pt) | Processo para a preparacao de um hidrato de beta-lactama cristalino | |
| JP2005525337A5 (enExample) | ||
| WO2009067856A1 (fr) | Inhibiteur de l'histone désacétylase, composition et utilisation de celui-ci | |
| KR100778256B1 (ko) | 치환 방향환 화합물, 그의 제조법 및 용도 | |
| ES2273077T3 (es) | Derivados de 2-fenilamino-4-trifluorometil-5 (bencil- o piridin-4-il-metil) carbamoilpirimidina como moduladores selectivos del receptor cannabinoide cb2. | |
| JP5826371B2 (ja) | ペメトレキセド塩の製造方法 | |
| JP2020528922A5 (enExample) | ||
| EP4172146A1 (en) | Substituted n-phenylacetamides having p2x4 receptor antagonistic activity |